Suchergebnisse - "Di Lernia, Vito"

PubPharm (9)

1

Guselkumab for the treatment of psoriasis : a 60-week real-life multicenter retrospective experience

enthalten in: Expert opinion on biological therapy | 2022

von Bardazzi, F. | Viviani, F. | Merli, Y. | +9

2

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis : A Multicentre, Real-Life Study

enthalten in: Paediatric drugs | 2022

von Napolitano, M. | Fabbrocini, G. | Neri, I. | +35

3

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis : SUPREME study

enthalten in: The British journal of dermatology | 2018

von Costanzo, A. | Bianchi, L. | Flori, M. | +53

4

IgA nephropathy during treatment with TNF-alpha blockers : Could it be predicted?

enthalten in: Medical hypotheses | 2017

von Di Lernia, V.

5

Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers : a retrospective study

enthalten in: The Journal of dermatological treatment | 2014

von Di Lernia, V. | Ricci, C. | Lallas, A. | +1

6

Cutaneous malignancies during treatment with efalizumab and infliximab : When temporal relationship does not mean causality

enthalten in: The Journal of dermatological treatment | 2011

von Di Lernia, V. | Ricci, C.

7

Successful treatment of hand and foot psoriasis with infliximab

enthalten in: Dermatology online journal | 2010

von Di Lernia, V. | Guareschi, E.

8

Progressive multifocal leukoencephalopathy and antipsoriatic drugs : assessing the risk of immunosuppressive treatments

enthalten in: International journal of dermatology | 2010

von Di Lernia, V.

9

Efalizumab and progression of undiagnosed follicular mycosis fungoides

enthalten in: Archives of dermatology | 2009

von Di Lernia, V.

CommentOn: Arch Dermatol. 2009 Jan;145(1):92-4. - PMID 19153358

1
[1]